Hangzhou Tian-Mu-Shan Stock Soars 7.66%, Hits Intraday High of CNY 22.75

Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.66% on March 27, 2026. The stock reached an intraday high of CNY 22.75, reflecting a strong day of trading for the small-cap company in the Pharmaceuticals & Biotechnology sector. In terms of performance metrics, Hangzhou Tian-Mu-Shan has shown impressive results over various time frames. Over the past year, the stock has surged by 93.8%, significantly outperforming the China Shanghai Composite, which recorded a gain of 16.01% during the same period. Year-to-date, the company has achieved a 29.98% increase, while its three-year performance stands at an impressive 164.71%. Despite these short-term gains, the company faces challenges in long-term growth, with a modest annual net sales growth rate of 1.15% over the last five years. Additionally, the company has a high debt-to-equity ratio of 2.33, indicating a reliance on debt financing. The return on equity is notably high at 50.44%, but the overall financial health suggests a need for careful consideration of its long-term fundamentals.